{"entity":{"id":"nct06911333","kind":"trial","name":"AD1208 in Subjects With Any Progressive, Locally Advanced or Metastatic Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of AD1208 in advanced solid tumours, run by Avelos Therapeutics Inc., now recruiting.","summary":"AD1208 in Subjects With Any Progressive, Locally Advanced or Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT06911333 by Avelos Therapeutics Inc., with 36 participants planned, started 2025-03-11 and due to reach its primary completion in 2029-06-30. Interventions recorded: AD1208.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06911333","url":"https://clinicaltrials.gov/study/NCT06911333"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06911333","phase":"1/2","setting":"A Phase I/IIa Trial of AD1208, a Cell Cycle Inhibitor/MASTL Inhibitor, as a Single Agent or a Combination in Subjects With Any Progressive, Locally Advanced(Unresectable) or Metastatic Solid Tumors","sponsor":"Avelos Therapeutics Inc.","enrolled":36,"outcomes":[]},"route":"/trials/nct06911333/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}]}}